SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Robert K. who wrote (8540)1/29/1999 9:16:00 AM
From: opalapril  Respond to of 17367
 
Time to get real. It seems to me the first P-3 trial to be announced will have a watershed effect on the stock price. If good, the stock rises dramatically and we won't be too concerned about this latest deal. If bad, it won't matter. To be sure, as Stephen Jay Gould has said, god resides in the details, but the only way the details will matter is if the P-3 results are ambiguous.



To: Robert K. who wrote (8540)1/29/1999 9:35:00 AM
From: BRAVEHEART  Read Replies (1) | Respond to of 17367
 
A guess on the financing. I would guess this financing is not set up to bury the company with dilutive convertables. I would assume it has certain provisions. Call them reset provisions. If the stock trades below a certain price {( risk protection ) in the event of say clinical failure } then the conversions are reset as of certain preset dates.

GENTA has such provisions. It seems as if they are set up on a six month basis. I would personally find out what those provisions are ( SEC documents etc ). Monitor the shareprice relative to certain risk factors ( FDA decisions and such ). If the trend is down heading into a reset and shorting behavior is up I might get out momentarily until the reset date passes. Just some thoughts...

Heck VRGN is experiancing the Death Spiral convertable right now. Should end soon. Looks like they are dragging it to .50. Should have a nice pop in the end.

BEST WISHES
LONE WOLF